TYNDALL JOSEPH A. 4
4 · Axogen, Inc. · Filed Jun 11, 2025
Insider Transaction Report
Form 4
Axogen, Inc.AXGN
TYNDALL JOSEPH A.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-06-10$7.04/sh+4,000$28,160→ 26,931 total - Exercise/Conversion
Common Stock
2025-06-10$6.30/sh+7,586$47,792→ 22,931 total - Exercise/Conversion
Employee Stock Option (right to purchase)
2025-06-10$7.04/sh−4,000$28,160→ 14,248 totalExercise: $7.04Exp: 2034-06-06→ Common Stock (4,000 underlying) - Sale
Common Stock
2025-06-10$10.72/sh−26,931$288,700→ 0 total - Exercise/Conversion
Stock Option (right to purchase)
2025-06-10$6.30/sh−7,586$47,792→ 0 totalExercise: $6.30Exp: 2033-09-01→ Common Stock (7,586 underlying)
Footnotes (3)
- [F1]The reported price in Column 4 is a weighted average sale price. These shares were sold on June 10, 2025 in multiple transactions at prices ranging from $10.69 to $10.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]Options vested on the first anniversary of the grant date, which was September 1, 2023.
- [F3]Options vested on the first anniversary of the grant date, which was June 6, 2024.